Patents Represented by Attorney Li Cai
-
Patent number: 7978309Abstract: A clamping apparatus capable of fixing a roll film is disclosed. The clamping apparatus includes: a carrier comprising a slot; a cover positioned in the slot; and a cannelure formed between the cover and the carrier, for guiding the film inserted from the first film door to a predetermined position. The cover includes: an upper ramp, positioned on one side of the cannelure opening, for guiding the film from the first film door to the cannelure opening, wherein a first edge of the upper ramp is near the cannelure opening, and a second edge of the upper ramp is away from the slot opening and inclines to the first edge of the upper ramp.Type: GrantFiled: July 2, 2006Date of Patent: July 12, 2011Assignee: Lite-On Technology CorporationInventors: Ta-Yi Lee, Jeicy Lee, Jy Tang
-
Patent number: 7273728Abstract: The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, the method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production; and (2) purifying the diphtheria toxin from the culture by contacting a toxin containing preparation derived therefrom with an ion exchange matrix, eluting a fraction containing the toxin, applying the eluate to a hydrophobic matrix, and eluting a fraction containing the toxin.Type: GrantFiled: August 15, 2005Date of Patent: September 25, 2007Assignee: GE Healthcare ASInventors: Henry Wolfe, Fahar Merchant, Rosemina Merchant, Christopher Black, Harry Storflor, Geir Stokke, Halldis Hellebust
-
Patent number: 7264792Abstract: A process for the production of an 18F-labelled tracer which comprises treatment of a solid support-bound precursor of formula (I): SOLID SUPPORT-LINKER-SO2—O-TRACER (I) with 18F— to produce the labelled tracer of formula (II)Type: GrantFiled: December 19, 2003Date of Patent: September 4, 2007Assignee: GE Healthcare LimitedInventors: Alexander Mark Gibson, Lynda Jane Brown, Richard Charles Downie Brown
-
Patent number: 7223891Abstract: The invention relates to a process for the production of an [18F]fluorohaloalkane which comprises treatment of a solid support-bound precursor of formula (I): SOLID SUPPORT-LINKER-SO2—O—(CH2)nX (I) wherein n is an integer of from (1) to (7) and X is chloro, bromo or iodo; with 18F? to produce the [18F]fluorohaloalkane of formula (II) 18F—(CH2)n—X (II) wherein n and X are as defined for the compound of formula (I), optionally followed by (i) removal of excess 18F?, for example by ion-exchange chromatography; and/or (ii) removal of organic solvent.Type: GrantFiled: December 19, 2003Date of Patent: May 29, 2007Assignee: Hammersmith Imanet Ltd.Inventors: Frank Brady, Sajinder Kaur Luthra, Yongjun Zhao
-
Patent number: 7198776Abstract: The invention relates to metal complex compounds, contrast agents for MRI and in vivo NMR markers for NMR spectroscopy comprising said metal complex compounds and methods for in vivo determination of physiological parameters, e.g. enzyme activity or pH using said metal complex compounds.Type: GrantFiled: November 28, 2002Date of Patent: April 3, 2007Assignee: GE Healthcare ASInventors: Jo Klaveness, Pal Rongved
-
Patent number: 7182934Abstract: The invention provides a composition of matter of formula I V-L-R ??(I) where V is an organic group having binding affinity for an angiotensin II receptor site, L is a linker moiety or a bond, and R is a moiety detectable in in vivo imaging of a human or animal body, with the provisos that where V is angiotensin or a peptidic angiotensin derivative or analog then V-L-R is other than a non-metal radionuclide substituted peptide (eg 125I substituted angiotensin II) and L-V is other than simply a peptide with a chelating agent amide bonded to a side chain thereof. This composition of matter may be used to image cardiovascular diseases and disorders.Type: GrantFiled: April 18, 2005Date of Patent: February 27, 2007Assignee: GE Healthcare ASInventors: Jo Klaveness, Anne Naevestad, Alan Cuthbertson
-
Patent number: 7173061Abstract: The invention provides compounds of formula (I) or a salt thereof, radiolabelled versions thereof, and their use in the diagnosis or in vivo imaging of Amyloid-associated diseases such as Alzheimer's diseaseType: GrantFiled: December 12, 2002Date of Patent: February 6, 2007Assignee: GE Healthcare LimitedInventors: Denis Raymond Christophe Bouvet, Harry John Wadsworth
-
Patent number: 7115249Abstract: The invention relates to compounds of formula (I); wherein R1 and R2 independently selected from C1-6 alkyl; P1, P2, P3, and P4 are each independently hydrogen or a protecting group; and their use in the preparation of 18F-labelled 6-L-fluorodopaType: GrantFiled: June 18, 2002Date of Patent: October 3, 2006Assignees: GE Healthcare Ltd., Hammersmith Imanet Ltd.Inventors: Sajinder Kaur Luthra, Frank Brady, Harry John Wadsworth
-
Patent number: 7060731Abstract: This application relates to the use of certain amines of formula (I) for combatting and preventing systemic and local complement activation, and in particular to the use of meglumine and derivatives and optionally salts thereof in combatting and preventing said activation. The amines are also of use in combatting activation of the kinin/kallikrein system or blood coagulation system.Type: GrantFiled: September 12, 2002Date of Patent: June 13, 2006Assignee: Amersham Health ASInventors: Anne Juelsrud, Gunn Ragnhild Hoigaard Bjerke
-
Patent number: 7052672Abstract: The present invention relates to stabilized 99mTc radiopharmaceutical compositions, which include both a radioprotectant and one or more antimicrobial preservative(s), and hence have an extended lifetime of use. The radioprotectant is ascorbic acid, para-aminobenzoic acid, gentisic acid or a salt thereof with a biocompatible cation, and the antimicrobial preservative is one or more compound from the paraben series of preservatives. The invention is particularly useful for cationic, lipophilic 99mTc heart imaging agents such as Myoview™.Type: GrantFiled: April 11, 2001Date of Patent: May 30, 2006Assignee: GE Healthcare LimitedInventors: Alan Michael Forster, David Edwards, Ole Kristian Hjelstuen
-
Patent number: 7049289Abstract: Synthetic analogues of lysine and glutamine are provided which function as substrates for the fibrin-stabilising enzyme Factor XIIIa even when labelled with a detectable moiety. The use of suitable protecting groups provides compounds which possess reduced susceptibility to in vivo metabolism especially by peptidases, and are hence useful agents for the diagnosis of thrombosis, embolism, atherosclerosis, inflammation or cancer.Type: GrantFiled: May 14, 1999Date of Patent: May 23, 2006Assignee: Amersham PLCInventors: Anthony Eamon Storey, Marivi Mendizabal, Susan Champion, Alex Gibson, Benedicte Guilbert, Ian Andrew Wilson, Peter Knox
-
Patent number: 7014839Abstract: The present invention relates to the use of particulate materials as contrast agents in in vivo light imaging.Type: GrantFiled: November 1, 2002Date of Patent: March 21, 2006Assignee: Amersham Health ASInventors: Jo Klaveness, Bjorn Fuglaas, Pål Rongved, Edvin Johannesen, Paul Mark Henrichs, Wolfgang Hans Heinrich Gunther, Edward Richard Bacon, John Luke Toner, Gregory Lynn McIntire, Vinay C. Desai
-
Patent number: 6974882Abstract: A process for the preparation of iodixanol by dimerization of 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-isophthalamide (“Compound A”) in which, after the dimerization step, unreacted Compound A is precipitated from the reaction mixture and recovered for re-use. The process substantially increases the net yield of iodixanol and simplifies its purification.Type: GrantFiled: August 6, 2001Date of Patent: December 13, 2005Assignee: Amersham Health ASInventor: Ole Magne Homestad
-
Patent number: 6962803Abstract: The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, said method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production; and (2) purifying the diphtheria toxin from the culture by contacting a toxin containing preparation derived therefrom with an ion exchange matrix, eluting a fraction containing the toxin, applying the eluate to a hydrophobic matrix, and eluting a fraction containing the toxin.Type: GrantFiled: October 22, 2003Date of Patent: November 8, 2005Assignee: Amersham Health ASInventors: Henry Wolfe, Fahar Merchant, Rosemina Merchant, Christopher Black, Harry Storflor, Geir Stokke, Halldis Hellebust
-
Patent number: 6921525Abstract: The invention provides a composition of matter of the formula (I): V-L-R where V is an organic group having binding affinity for an angiotensin II receptor site, L is a linker moiety or a bond, and R is a moiety detectable in in vivo imaging of a human or animal body, with the provisos that where V is angiotensin or a peptidic angiotensin derivative or analog then V-L-R is other than a non-metal radionuclide substituted peptide (e.g. 125I substituted angiotensin II) and L-V is other than simply a peptide with a chelating agent amide bonded to a side chain thereof. This composition of matter may be used to image cardiovascular diseases and disorders.Type: GrantFiled: February 21, 2003Date of Patent: July 26, 2005Assignee: Amersham Health ASInventors: Jo Klaveness, Anne Naevestad, Alan Cuthbertson
-
Patent number: 6906171Abstract: The synthesis of peptides comprising disulphide bridges is challenging since it is difficult to ensure that the correct cysteine residues combine to form the desired disulphide bridges. The present invention describes novel protection techniques useful in the preparation of peptides. Described is a process for the deprotection of an Acm-, MBzl- and/or tBu-protected thiol which comprises reacting said protected thiol with an acid in the presence of an oxidising agent at a temperature sufficient to effect deprotection and generation of disulphide bonds.Type: GrantFiled: January 18, 2002Date of Patent: June 14, 2005Assignee: Amersham Health ASInventor: Alan Cuthbertson
-
Patent number: 6875420Abstract: Disclosed herein are agents for enhancing the contrast in an ultrasound image. These agents are extremely small bubbles, or “microbubbles,” comprised of specially selected gases. The microbubbles described herein exhibit long life spans in solution and may be produced at a size small enough to traverse the lungs, thus enabling improved ultrasound imaging of the cardiovascular system and other vital organs. Also disclosed herein is a method for selecting gases from which contrast agents may be produced. The method is based on calculations using inherent physical properties of gases and describes a means to associate the properties of a gas with the time for dissolution of microbubbles comprised of the gas.Type: GrantFiled: July 18, 1997Date of Patent: April 5, 2005Assignee: Amersham Health ASInventor: Steven C. Quay
-
Patent number: 6811766Abstract: A combined preparation comprising: i) an ultrasound contrast agent capable of accumulation in tissue microvasculature; and ii) a pharamacologically effective amount of a vasodilator drug may be used in perfusion imaging, especially of the myocardium. The contrast agent accumulates in tissue in concentrations related to the regional rate of tissue perfusion, and the vasodilator drug enhances distinction between normally perfused and underperfused tissue.Type: GrantFiled: April 20, 2000Date of Patent: November 2, 2004Assignee: Amersham Health ASInventors: Morten Eriksen, Jonny Østensen, Sigmund Frigstad, Pål Rongved
-
Patent number: 6806045Abstract: A method for the identification and characterization of a receptor in target tissue for which a selected vector has affinity, wherein a transfected cell line expressing the receptor is added to a suspension of encapsulated microbubbles to which the selected vector is coupled and allowing the microbubbles and cells coupled thereto to float to the surface of the suspension. Upon isolating the microbubble-bound cells at the surface, these may be cultured to study the receptor, or cells may be lysed, amplifying the receptor-encoding cDNA and sequencing the cDNA.Type: GrantFiled: January 18, 2002Date of Patent: October 19, 2004Assignee: Amersham Health ASInventors: Mari Ann Kulseth, Dagfinn Lovhaug, Aslak Godal
-
Patent number: RE38856Abstract: The invention provides a process by which ultra low salt content triiodinated aromatic compounds may be isolated from a highly acidic hot triiodination raction reaction medium in a straightforward fashion. The process involves increasing the pH to above 5 a value in the range of 3 to 7 with sodium hydroxide, addition of sodium bisulphite and/or sodium dithionite, addition of seed crystals, cooling slowly, and washing the collected precipitate with water.Type: GrantFiled: October 24, 2002Date of Patent: October 25, 2005Assignee: Amersham Health ASInventors: William Thielking, Einar Odd Ingvoldstad, Trygve Gulbrandsen